0001415889-25-000599.txt : 20250103 0001415889-25-000599.hdr.sgml : 20250103 20250103173840 ACCESSION NUMBER: 0001415889-25-000599 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20250102 FILED AS OF DATE: 20250103 DATE AS OF CHANGE: 20250103 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Nolan Sean P. CENTRAL INDEX KEY: 0001569926 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39536 FILM NUMBER: 25508139 MAIL ADDRESS: STREET 1: C/O INTERMUNE, INC. STREET 2: 3280 BAYSHORE BLVD. CITY: BRISBANE STATE: CA ZIP: 94005 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Taysha Gene Therapies, Inc. CENTRAL INDEX KEY: 0001806310 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 843199512 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3000 PEGASUS PARK DRIVE STREET 2: SUITE 1430 CITY: DALLAS STATE: TX ZIP: 75247 BUSINESS PHONE: (214) 612-0000 MAIL ADDRESS: STREET 1: 3000 PEGASUS PARK DRIVE STREET 2: SUITE 1430 CITY: DALLAS STATE: TX ZIP: 75247 4 1 form4-01032025_100137.xml X0508 4 2025-01-02 0001806310 Taysha Gene Therapies, Inc. TSHA 0001569926 Nolan Sean P. C/O TAYSHA GENE THERAPIES, INC. 3000 PEGASUS PARK DRIVE, SUITE 1430 DALLAS TX 75247 true true false false Chief Executive Officer 0 Common Stock 2025-01-02 4 A 0 892500 0 A 2078358 D Common Stock 1535545 I See footnote Employee Stock Option (right to buy) 1.85 2025-01-02 4 A 0 892500 0 A 2035-01-02 Common Stock 892500 892500 D Represents a restricted stock unit ("RSU") award. The RSU grant was approved by the Issuer's compensation committee of the board of directors and will be effective as of the date the Issuer has an effective Registration Statement on Form S-8 registering the shares available for issuance under the 2020 Stock Incentive Plan. The RSUs will vest in four equal annual installments beginning on January 2, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. The securities are held by Nolan Capital, LLC (the "LLC"). The Reporting Person is the President of the LLC and has shared voting and investment power with respect to the shares held by the LLC. 25% of the total number of shares underlying the option shall vest and become exercisable on January 2, 2026 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. /s/ Kamran Alam, Attorney-in-Fact 2025-01-03